Australia
Matthew Swinn, who leads the firm’s IP practice, discusses why Mallesons is well-placed to remain a major IP force
Leighton Cassidy Legal hopes to leverage its founder's international experience and provide clients with a rare chance to receive litigation and prosecution under one umbrella
Anita Cade, head of Ashurst’s IP and media team in Australia, discusses why law firms that can pull together capability across different practice areas and jurisdictions stand to gain
Newly independent King & Wood has established offices in North America, while Mallesons has entered a ‘new era’ with a 1,200-lawyer firm across Australia and Singapore
Sponsored
Sponsored
-
Sponsored by Griffith HackSoftware and patents have always had a difficult relationship. Around the world, different rules in different jurisdictions create uncertainty for innovators wanting to know if their key innovations can be secured or whether the market is a free-for-all against competitors. -
Sponsored by Griffith HackTrack and trace smartphone applications used in the fight against COVID-19 are representative of a relatively new industry falling between the healthcare, IT, medical devices and pharmaceutical sectors.
-
Sponsored by Griffith HackMānuka is the Māori name for the Leptospermum scoparium, a species of flowering plant in the myrtle family, Myrtaceae. Mānuka nectar is renowned for producing 'liquid gold', a pure honey possessing unique medicinal and antibacterial qualities.
-
Sponsored by Griffith HackIn early 2019, IP Australia initiated a comprehensive research phase exploring Australia’s design ecosystem, including voices from the industry, design forums, economic analysis and business surveys. Following this 12-month exercise, the regulator has proposed the following changes:
-
Sponsored by Griffith HackDespite being a market of only 26 million people, Australia possesses a world-class healthcare system and well regarded scientific community. This is most recently demonstrated through the participation of Australian scientists in the race to successfully manufacture a COVID-19 vaccine, and by the low infection death rates from the current pandemic in Australia.
